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Abstract
Novel inhibitors of the urokinase-mediated plasminogen
(plg) activation system are potentially of great clini-
cal benefit as anticancer treatments. Using phage dis-
play, we identified DX-1000 a tissue factor pathway
inhibitor–derived Kunitz domain protein which is a
specific high-affinity inhibitor of plasmin (pln) (Ki =
99 pM). When tested in vitro, DX-1000 blocks plasmin-
mediated pro-matrix metalloproteinase-9 (proMMP-9)
activation on cells and dose-dependently inhibits tube
formation, while not significantly affecting hemostasis
and coagulation. However, this low–molecular weight
protein inhibitor (f7 kDa) exhibits rapid plasma clear-
ance in mice and rabbits, limiting its potential clinical
use in chronic diseases. After site-specific PEGylation,
DX-1000 retains its activity and exhibits a decreased
plasma clearance. This PEGylated derivative is effective
in vitro, as well as potent in inhibiting tumor growth of
green fluorescent protein (GFP)–labeled MDA-MB-231
cells. 4PEG–DX-1000 treatment causes a significant re-
duction of urokinase-type plasminogen activator (uPA)
and plasminogen expressions, a reduction of tumor
proliferation, and vascularization. 4PEG–DX-1000 treat-
ment significantly decreases the level of active mitogen-
activated protein kinase (MAPK) in the primary tumors
and reduces metastasis incidence. Together, our re-
sults demonstrate the potential value of plasmin inhibi-
tors as therapeutic agents for blocking breast cancer
growth and metastasis.
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Introduction
Plasmin (pln), a 90-kDa broad-spectrum protease of tryptic
specificity, plays a central role in the fibrinolytic process in
regulating the turnover of extracellular matrix (ECM) com-
ponents [1–3]. Pln is present in the blood in its inactive
zymogen form plasminogen (plg) [4]; its active form being
rapidly inhibited in the systemic circulation by a2-antiplasmin
and a2-macroglobulin [5]. Conversion of plg to active pln is
catalyzed by urokinase-type plasminogen activator (uPA) or
tissue-type plasminogen activator (tPA). Whereas tPA is ac-
cepted to be primarily involved in thrombolysis, it is mainly uPA
that generates active pln leading to local ECM breakdown [6–
8]. The uPA bound to the membranous urokinase-type plas-
minogen activator receptor (uPAR) increases plg activation and
subsequent pln-dependent proteolysis [9–11]. When pln is
bound to the cell surface, it is protected from a2-antiplasmin–
mediated inhibition confining proteolysis locally at or near the
cell surface [11–13]. Pln plays a major role in pathologic
conditions such as inflammation, tumor cell growth, and me-
tastasis formation [7,14]. Invasive properties of tumor cells may
be at least partially dependent on direct pln-mediated proteol-
ysis of the ECM [15] and indirectly dependent on the activation
of latent pro-matrix metalloproteinases (proMMPs) and colla-
genases by pln [9,16–18]. The pln cascademay activate MMP-
3 and MMP-9 through the uPA/uPAR complex at the cell sur-
face accelerating the tumorigenic effects [17,19]. Pln induces
the permeability of blood vessels [20] and thereby facilitates the
systemic dissemination of tumor cells.
Pln and MMPs may also play additional roles in angiogen-
esis [21–23] by releasing specific matrix-derived growth fac-
tors including basic fibroblast growth factor and vascular
endothelial growth factor [24] and in the activation of latent
transforming growth factor–beta [25–27], insulin-like growth
factor-1, and insulin-like growth factor–binding protein. More-
over, endothelial cells at the leading edge of a new blood vessel
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express components of both pln and MMP systems and their
expression is regulated by the same growth factors and
cytokines [28]. Thus, pln is an attractive target for cancer
therapy because: (a) this enzyme is predominantly present in
its inactive zymogen form, with its active form being mostly
present locally in tissues undergoing remodeling, e.g.
tumors; (b) it is one of the major enzymes directly and/or
indirectly involved in degradation of the ECM; and (c) it
stimulates angiogenesis.
We have described the use of phage display to identify a
human Kunitz domain–based inhibitor of human pln [29].
The protein, DX-1000, is a potent (Ki = 99 pM) and highly
specific inhibitor of pln. Because of its low molecular weight,
the protein exhibits a rapid plasma clearance rate in vivo.
Therefore, we prolonged in vivo circulation time of DX-1000
by conjugation with poly(ethylene glycol) (PEG). In the
present work, we demonstrate the specificity of DX-1000
for pln, its minor effect on hemostasis and coagulation
in vitro, and its potency in vitro as an antiproteolytic and
antiangiogenic agent. We also describe the PEGylated de-
rivative of DX-1000 (4PEG–DX-1000), its in vitro and in vivo
inhibitory properties, its slow clearance, and its high stability.
Materials and Methods
Production and Purification of DX-1000
DX-1000 (7167 Da) was produced and purified as de-
scribed previously [29].
Hemostasis Studies
Blood from healthy donors was collected in trisodium cit-
rate (Vacutainer; Becton Dickinson, Oxford, UK) and plasma
was prepared by centrifugation at 2000g for 15 minutes.
Fibrinolysiswasmeasured by Euglobulin Clot Lysis Time and
fibrin plate lysis (Dr Ian Mackie, Hematology Department,
University College London, London, UK), using standard tech-
niques in the presence and absence of 5 mg/ml dextran sul-
fate. Fibrin plates were prepared using plg-rich fibrinogen
(Quadratech Ltd, Epsom, UK) and bovine thrombin (Diag-
nostic Reagents Ltd, Oxford, UK), in six-well culture plates
standardized using Reference Plasma 100% (Technoclone
Ltd, Dorking, UK). Plasma clot lysis was studied using 0.5 mM
rec-tPA (Quadratech) and citrated plasma with thrombin and
CaCl2 (0.7 U/ml and 0.6mM, respectively) in amicroplate [30].
The formation and dissolution of the clot were monitored as
the serial change in optical density at 405 nm. The time taken
to reach 50% lysis was calculated graphically. Prothrombin
time (Innovin; Dade Behring, Marburg, Germany, or PT-Fib
HS Plus; Instrumentation Laboratory, Lexington, MA), throm-
bin time (Thromboclotin; Dade Behring), activated partial
thromboplastin time (APTT) (Actin FS, Actin FSL, or Pathrom-
tin SL; Dade Behring), and Clauss fibrinogen (Thrombin Re-
agent; Dade Behring) were measured using an analyzer
(CA-7000; Sysmex, Kobe, Japan). Whole blood clotting time
wasmeasured using unanticoagulated, freshwhole blood on a
coagulometer (KC4A Amelung; Trinity Biotech, Bray, Ireland).
Platelet function was studied using a platelet function ana-
lyzer (PFA-100; Dade Behring). Thrombelastography (TEG)
was studied using citrated blood at 30 to 120 minutes from
venepuncture, in the presence of kaolin, using a thrombelas-
tographic analyzer (TEG-5000; Medicell, London, UK) and
then recalcification. In some experiments, 1 mg/ml tPA (Quad-
ratech) was added to induce fibrinolysis at the time of mixing
with kaolin.
Plasminogen assays were performed using streptokinase
and the amidolytic substrate H-D-Val-Leu-Lys-OH.pNA
(Channel Diagnostics, Walmer, UK) in a microtiter technique.
Protein C was assayed using an activator (Protac) and the
amidolytic substrate Unitrate PC, 2AcOH.H-D-Lys(Cbo)-Pro-
Arg-pNA (Technoclone Ltd). The effect of DX-1000 on acti-
vated protein C (rAPC, a kind gift of Eli-Lilly, Indianapolis, IN)
activity was studied in a microtiter amidolytic assay using
6.2 mg/ml (rAPC) and Unitrate PC substrate.
Preparation of PEGylated DX-1000
DX-1000 in PBS was reacted with a 40-fold molar excess
of methoxy-PEG-succinimidyl propionate (mPEG-SPA, Mr
5000; Shearwater Polymers, Huntsville, AL), in terms of total
primary amino groups of DX-1000, at 4jC for 3 hours. The
reaction was stopped with a 10-fold molar excess of glacial
acetic acid. The 4PEG–DX-1000 was characterized by
SDS-PAGE, analytical size-exclusion high-performance liquid
chromatography (SE-HPLC), and mass analysis usingmatrix-
assisted laser desorption/ionization time of flight. The specific
inhibitory activity of DX-1000 after PEGylation was deter-
mined as previously described [29]. Briefly, DX-1000 and
4PEG–DX-1000 were incubated with 2 nM human pln at
30jC for 1 hour. Then, N-succinyl-Ala-Phe-Lys 7-amido-4-
methylcoumarin acetate (Sigma-Aldrich, St. Louis, MO) was
added to a final concentration of 100 mM. Measurements were
taken on a Gemini plate reader with excitation at 360 nm and
emission read at 460 nm. Plots of enzymatic rate versus in-
hibitor concentration were generated by nonlinear regression
using SigmaPlot 8.0 to obtain Ki estimates:
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where:
Ki = inhibition constant
DX1000 = total DX-1000 concentration
E = total human pln concentration (determined by active
site titration)
Endotoxin levels of purified 4PEG–DX-1000 were mea-
sured using a commercially available Limulus Amebocyte
Lysate (LAL) kinetic turbidimetric/PyroTurb ES (Glucoshield)
method (Associates of Cape Cod, Inc., E. Falmouth, MA)
and were consistently < 0.2 endotoxin units/mg.
Cell-Based Assays and Gel Zymography
Cells and cell culture HT-1080, MDA-MB-231, and HL-
60 cells were obtained from the American Type Culture
Collection (Rockville, MD). HT-1080 cells were cultured in
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complete medium [RPMI 1640, 25 mM Hepes (Cambrex,
Verviers, Belgium), 10%heat-inactivated fetal calf serum (FCS)
(Life Technologies – Invitrogen SA, Merelbeke, Belgium), 2%
amphotericin B (Fungizone; Life Technology – Invitrogen), and
1% penicillin–streptomycin (Life Technologies – Invitrogen)].
HL-60 cells were grown in RPMI supplemented with 25 mM
Hepes and 15% heat-inactivated FCS. Cultures were main-
tained at a cell concentration between 1  105 and 1  106
per ml. Cells transfected with green fluorescent protein
(MDA-MB-231–GFP) were cultured as previously described
[31]. Human umbilical vein endothelial cells (HUVECs) were
freshly isolated from umbilical cords and cultured on gelatin-
coated culture dishes in RPMI 1640 with 25 mM Hepes sup-
plemented with growth factors (EGM SingleQuots; Cambrex),
200 mM L-glutamine, 1% penicillin–streptomycin, and 10%
FCS. LEII mouse lung endothelial cells were a generous gift
from Dr. Kari Alitalo, University of Helsinki. They were cultured
in minimum essential medium containing Glutamax and
Earl’s Salts (Gibco, Life Technologies – Invitrogen) supple-
mented with 10% FCS.
Gelatin zymography. Gelatinolytic activities were ana-
lyzed by zymography as previously described [32]. Briefly,
HL-60 cells (2 105) were grown for 24 hours, washed twice
in PBS and incubated in the presence or absence of pln
(10 mU/ml) and proMMP-3 (10 nM) in serum-free medium
(Ultraculture medium; Cambrex) supplemented with 1%
L-glutamine and 1% penicillin–streptomycin. In some condi-
tions, DX-1000 or 4PEG–DX-1000 (1 mM) was added to block
pln activity. After 48 hours, conditioned media were collected
and concentrated 10-fold using centrifugal filter units (Centri-
con YM-30 columns; Millipore, Brussels, Belium). Then sam-
ples (30 mg protein/sample) were diluted in nonreduced SDS
sample buffer and proteins were resolved by electrophoresis
in 10% SDS–polyacrylamide gels copolymerized with 1 mg/ml
gelatin. Gels were washed with 2.5% Triton X-100 for 1 hour
and twice in Tris–HCl (pH 8.0) for 15 minutes at room tem-
perature. The gels were incubated with substrate buffer
[50 mM Tris–HCl (pH 8.0) and 10 mM CaCl2] for 18 hours
at 37jC. The gels were then stained with Coomassie brilliant
blue R-250 and destained until clear bands of lysis appeared.
Conditionedmedium fromHT-1080 cells treated with 20 ng/ml
phorbol 12-myristate acetate served as a standard. To con-
firm the lytic bands, gels were treated with 20 mM EDTA (a
metalloproteinase inhibitor) in the substrate buffer for 18 hours
at 37jC.
Casein zymography. Serum-free samples were pre-
pared as above and loaded onto gels containing b-casein
as substrate (Zymo Blue Casein Gel; Invitrogen). On staining
with Coomassie brilliant blue and destaining, the final gel had
a uniform background except in regions to which serine
proteases had migrated and cleaved the casein. Recombi-
nant uPA served as a positive control. Molecular standards
were used to calibrate molecular weights.
Tube formation assay. HUVECs (passage 2) were
seeded at 6  104/100 ml per well on collagen gel (50 ml of
rat tail collagen type I, 1.5 mg/ml; Serva, Belgium) in culture
medium and allowed to spread for 1.5 hour. The cells then
were covered with a new layer of collagen type I (1.5 mg/ml,
new preparation, 50 ml/well). After polymerization of the gel,
culture medium was added to each well in the presence or
absence of increasing concentrations of DX-1000 or 4PEG–
DX-1000 (ranging from 0.1 nM to 10 mM). Mouse LEII lung
endothelial cells were seeded at a density of 2  104 cells/
well on top of aMatrigel layer according to the manufacturer’s
guidelines (BD Biosciences, Bedford, MA). Culture medium
was added to each well in the presence or absence of
appropriate concentrations of DX-1000 or 4PEG–DX-1000.
Cells were incubated at 37jC and 5%CO2 for 16 to 18 hours.
Tube length quantification and IC50 determination. En-
dothelial cell tube formation was assessed with an inverted
photomicroscope. Microphotographs of the center of each
well at low power were taken with a camera (Nikon; Nikon
Belux, Brussels, Belgium). Tube formation in the microphoto-
graphs was quantitatively analyzed (total tube length) with
an imaging software (MetaVue, Downingtown, PA). Tube for-
mation of untreated HUVECswas used as a negative control.
The assay was performed three times in triplicate. SigmaPlot
8.0 was used to determine IC50 values.
Animal Protocols
All animal protocols were in accordance with and ap-
proved by the institutional review board. For in vivo pharma-
cokinetics and stability studies of DX-1000 and 4PEG–DX-
1000, normal female BALB/c mice and naive New Zealand
White rabbits were used. The radiolabeled preparations
(IODO-GEN; Pierce Chemical Company, Rockford, IL)
[33,34] were injected into the mice through the tail vein and
into the rabbits through an ear vein. At predetermined times
postadministration, animals were sacrificed and blood sam-
ples were taken for radiation counting to determine clearance
rates and for SE-HPLC on Superose 12 (Amersham Bio-
sciences, Pittsburgh, PA) to test for stability. Specific accu-
mulation of 125I–DX-1000 and 125I–4PEG–DX-1000 in
mouse liver, heart, kidney, lung, spleen, stomach, intestine,
and muscles were also assessed. Data on in vivo pharma-
cokinetic parameters obtained from rodents and rabbits were
extrapolated to humans by interspecies scaling [35,36].
For xenograft studies, 4- to 6-week-old female BALB/c
mice (National Cancer Institute, Fredrick, MD) were used.
Before inoculation, culturedMDA-MB-231–GFP were washed
with Hank’s balanced buffer and centrifuged at 1500 rpm for
5 minutes. Cell pellets (5  105 cells/mouse) were resus-
pended in 100 ml of Matrigel (Becton Dickinson Labware) and
saline mixture (20% Matrigel) and injected subcutaneously
into the mammary fat pad of mice. All animals were num-
bered and kept separately in a temperature-controlled room
on a 12-hour/12-hour light/dark schedule with food and water
ad libitum [31,37]. Tumors were allowed to grow and ran-
domized to average volume of 60 to 70 mm3 in each group
and treated with 4PEG–DX-1000 (0.1, 1, and 10 mg/kg
every day) or vehicle alone through intraperitoneal route
for 4 weeks from the time of randomization of animals.
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All animals were monitored for any potential side effects
throughout the course of these studies. Tumor volumes were
determined from caliper measurement at weekly intervals by
two independent observers blinded to experimental groups.
Administration was discontinued after 4 weeks, the ani-
mals were sacrificed and their lungs, liver, and spleen as well
as the primary tumors were removed for further analysis.
Lungs, liver, and spleen were sliced to 1-mm-thick slices of
fresh tissue for direct examination under the fluorescent
microscope for the presence of GFP-expressing tumor foci.
The number of GFP-expressing tumor foci per field of
examination was counted as previously described [37].
Immunohistochemistry
Immunohistochemistry was carried out as previously
described using the avidin–biotin–peroxidase complex
method [38,39]. The antibodies used were monoclonal anti-
bodies against CD31 (1:50) (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA); Ki-67 (1:100) (Dako, Carpinteria, CA); uPA
(1:50) (American Diagnostica Inc., Stamford, CT); plg (Amer-
ican Diagnostica Inc.); and rabbit polyclonal antibodies
against mitogen-activated protein kinase (MAPK) and phos-
phorylatedMAPK (pMAPK; 1:50) (Cell Signaling Technology,
Beverly, MA) overnight at 4jC [37–39]. Biotinylated goat
anti–mouse or goat anti–rabbit antibodies (Vector Labora-
tories Inc., Burlingame, CA) were used as the secondary
antibodies at 1:200 for 30 minutes at room temperature. The
slides were treated with Vectastain ABC-AP kit (Vector
Laboratories Inc.) (1:200) for 30 minutes at room tempera-
ture. The signals were visualized with Fast Red TR/Naphthol
AS-MX phosphate (Sigma-Aldrich) containing 1 mM levami-
sole for 10 to 15 minutes. The sections were then counter-
stained with hematoxylin (Fisher Scientific, Ltd., Nepean,
ON, Canada) and mounted with Kaiser’s glycerol jelly. All
sections were washed three times, 10 minutes each, with
Tris buffer (pH 7.6) after each step. Negative controls
included substitution of the primary antibody with PBS.
Immunostaining of all tissues was quantitatively analyzed
by using a computer-assisted image analysis system as
previously described [40].
Statistical Analysis
Results are expressed as means ± SEM of at least
triplicate determinations and statistical comparisons are
based on Student’s t test and analysis of variance (ANOVA).
A P value of < .05 was considered significant.
Figure 1. PEGylation scheme and activity measurements. (A) Model of the structure of DX-1000. The locations of Lys-10, Lys-54, and Lys-55 are shown. (B)
PEGylation scheme. (C) Ki measurements for the inhibition of human pln by DX-1000 (left-hand panel) and 4PEG–DX-1000 (right-hand panel). Closed circles
show measured values for activity. For each sample, the solid line shows the fit of the equation for a tight binding inhibitor by nonlinear regression. The values for
total active enzyme (Etotal) and Ki obtained from each fit are shown.
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Results
DX-1000 Has Potent Plasmin Inhibitory Activity
DX-1000 inhibits pln with high affinity (Ki = 99 pM) [29,41]
and shows no significant inhibition of human uPA (Kif 60 mM)
or tPA (Ki f10 mM). DX-1000 does not crossreact with hu-
man plasminogen. DX-1000 also inhibits pln from mouse, rat,
rabbit, and chicken (Kif 100 pM).
DX-1000 Does Not Significantly Affect Hemostasis and
Coagulation In Vitro
When DX-1000 was added to plasma before euglobulin
precipitation, no significant inhibition of clot lysis was ob-
served using doses of up to 700 nM. In thrombelastography
experiments, there was a small, but nonsignificant increase
in the lag (r) time, but clotting time, rate, and maximal
amplitude remained within the normal range, using 140 to
560 nM DX-1000. In the presence of tPA, fibrinolysis was
inhibited in a dose-dependent manner [Ly30 for control, 140,
280, and 560 nM DX-1000 (mean ± SD): 71 ± 21, 64 ± 24,
46 ± 35 (P < .05), and 23 ± 16 (P < .001); Ly60: 86 ± 9, 82 ±
12, 67 ± 24 (P < .05), and 46 ± 22 (P < .005)]. We did not
observe an effect of DX-1000 on prothrombin time, thrombin
time, or Clauss fibrinogen assays at doses up to 5.6 mM.
There were no significant effects of DX-1000 on activated
partial thromboplastin time at concentrations up to 700 nM.
No clinically significant effects of DX-1000 were observed on
platelet function or whole blood coagulation time and we
observed no interference in plasma assays of plg or protein
C, as well as an absence of inhibition of activated protein C.
Figure 2. Evaluation of DX-1000 and 4PEG–DX-1000 in cell-based assays. (A) Modulation of proMMP-9 activation. Gelatin zymogram of media conditioned by
HL-60 cells cultured in the presence or absence of 4PEG–DX-1000 (1 M) DX-1000 (1 M) with or without plasmin (10 mU/ml) and proMMP-3 (10 nM).
Conditioned medium of HT-1080 cells treated with phorbol 12-myristate acetate (20 ng/ml) was used to identify the gelatinolytic species. (B) Scheme depicting the
blocking effect of DX-1000 or 4PEG–DX-1000 (illustrated by crosses) on proMMP-9 activation in HL-60 cells. (C) Expression of uPA by endothelial cells. Casein
zymogram of media conditioned by LEII cells or HUVEC. Recombinant uPA (rec-uPA) was used as a positive control. Molecular standards were used to calibrate
molecular weights. (D) Inhibitory effect of DX-1000 and 4PEG–DX-1000 on tube formation of HUVECs and LEII cells. Representative photomicrographs (left-hand
panel) show three-dimensional cultures of HUVEC treated with (a) vehicle alone, (b) DX-1000 (10 nM), or (c) 4PEG–DX-1000 (10 nM) and three-dimensional
cultures of mouse LEII cells treated with (d) vehicle alone, (e) DX-1000 (10 nM), or (f) 4PEG–DX-1000 (10 nM). IC50 values for DX-1000 and 4PEG–DX-1000
inhibition of tube formation (right-hand panel). Results are the means ± SEM of three such experiments.
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Aprotinin was used as a reference reagent; it demonstrated
inhibition of pln and activated protein C, inhibited clot lysis,
and prolonged the activated partial thromboplastin time, in
line with its known effects.
4PEG–DX-1000 Remains a Potent Inhibitor of Plasmin
We used amine reactive chemistry to couple 5-kDa
PEG moieties specifically to four sites on DX-1000: three
lysine residues (at positions 10, 54, and 55) and the amino-
terminus. All four PEGylation sites are positioned distal to
the portion of the inhibitor that interacts with pln (Figure 1, A
and B). The final PEGylated DX-1000 (4PEG–DX-1000)
molecule was purified by gel filtration HPLC. SDS-PAGE
analysis demonstrated purity levels of approximately 100%.
Matrix-assisted laser desorption/ionization time of flight anal-
ysis confirmed the expected mass of the 4  5 kDa PEGy-
lated DX-1000 product to be f27,600 Da. Whereas
PEGylation increased the Ki value for plasmin by 2.5-fold
(Ki = 99 pM for DX-1000; Ki = 232 pM for 4PEG–DX-1000)
(Figure 1C), it remained a potent inhibitor of plasmin.
Figure 3. Pharmacokinetics of DX-1000 and 4PEG–DX-1000 after intravenous injection in mice and rabbits. (A) In vivo plasma clearance curves for 125I-labeled
DX-1000 (closed diamonds) and for 4PEG–DX-1000 (diamonds) in mice (left-hand panel) and rabbits (right-hand panel). For in vivo pharmacokinetics studies,
normal female BALB/c mice and naive New Zealand White rabbits were used. The radiolabeled preparations were injected into the mice through the tail vein and
into the rabbits through an ear vein. At predetermined times postadministration, animals were sacrificed and blood samples were taken for radiation counting to
determine clearance rates. Data are calculated as percent-injected dose per milliliter plasma (%ID/ml) and are presented as a function of elapsed time
postadministration in minutes. The %ID/ml data are plotted on a logarithmic scale. The solid curve through each set of data is the four-parameter, least-squares fits
to the data of the biexponential equation: y = Aeat + Bet. (B) Biodistribution of 125I –DX-1000 (left-hand panel) and 125I –4PEG–DX-1000 (right-hand panel) in
mice. Insert within each panel shows time point. Sm. Int., small intestine; Lg. Int., large intestine.
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DX-1000 and 4PEG–DX-1000 Block Plasmin-Mediated
proMMP-9 Activation in Tumor Cells
MMPs are produced as zymogen and it has been sug-
gested that physiological activation of proMMP-9 involves
pln. HL-60 cells constitutively produced significant amounts
of proMMP-9 (Figure 2A, lane 1). Treatment of HL-60 cells
with pln (10 mU/ml) and proMMP-3 (10 nM) led to the pro-
cessing of endogenous proMMP-9 to active MMP-9 (Fig-
ure 2A, lane 2). ProMMP-9 remained latent after treatment of
the cells with DX-1000 or 4PEG–DX-1000 alone (Figure 2A,
lanes 3 and 5 ) or a combination of DX-1000 (or 4PEG–DX-
1000) with pln and proMMP-3 (Figure 2A, lanes 4 and 6).
PEG alone did not show any effect (Figure 2A, lanes 7 and
8). These results show the potency of DX-1000 and 4PEG–
DX-1000 to efficiently inhibit plasmin-mediated activation of
proMMP-9 in HL-60 cells (illustrated in Figure 2B).
DX-1000 and 4PEG–DX-1000 Inhibit Tube Formation By
Endothelial Cells
During angiogenesis, endothelial cells use uPA to migrate
and degrade the basement membrane surrounding capillary
blood vessels. Casein zymography revealed constitutive
expression of uPA in both human and mouse endothelial
cells (HUVEC and LEII cells) (Figure 2C). Endothelial cells
have the ability to form capillary-like structures when they are
embedded in a 3D matrix, i.e., collagen for HUVEC (Fig-
ure 2D, a) and Matrigel for mouse LEII cells (Figure 2D, d ).
Treatment with DX-1000 or 4PEG–DX-1000 inhibited tube
formation of HUVEC (Figure 2D, b and c) (IC50 = 1.4 ± 0.3 nM
for DX-1000 and 8.3 ± 1.6 nM for 4PEG–DX-1000) and of
LEII cells (Figure 2D, e and f ) (IC50 = 16.6 ± 0.1 nM for DX-
1000 and 15.8 ± 0.6 nM for 4PEG–DX-1000).
PEGylation of DX-1000 Substantially Decreases Plasma
Clearance in Rodents
The pharmacokinetic properties of DX-1000 were typical
for a Kunitz domain protein with a rapid clearance from
the circulation (b phase half-life = 27 minutes in mice and
1 hour in rabbits) (Figure 3A; Tables 1 and 2). PEGylation of
DX-1000 substantially decreased the clearance rate in
mice with the b phase half-life increasing by about 25-fold
in mice (Figure 3A, left-hand panel; Table 1) and nearly
60-fold in rabbits (Figure 3A, right-hand panel; Table 2).
Biodistribution studies in mice showed that 4PEG–DX-
1000 did not accumulate into the kidneys, in contrast to
DX-1000 (Figure 3B). SE-HPLC analyses of plasma sam-
ples taken frommice and rabbits demonstrated the presence
of intact 4PEG–DX-1000 in circulation one or more days
postadministration (data not shown). From the pharmacoki-
netic data obtained in mice and rabbits, we estimated a
circulating half-life for 4PEG–DX-1000 of about 14 days in
humans [35,36].
4PEG–DX-1000 Blocks Human Breast Cancer Growth and
Tumor Metastasis In Vivo
MDA-MB-231 cells stably transfected with GFP have
similar growth and invasive characteristics to wild type cells
and allow for the determination of the number and size of
microscopic GFP-positive cells [31,37]. 4PEG–DX-1000
administration as monotherapy resulted in a significant
decrease of primary tumor growth (f43%) (P < .05) with
4PEG–DX-1000 at 10 mg/kg (P < .05) without any no-
ticeable side effects including any change in body weight
(Figure 4A).
To evaluate the effect of 4PEG–DX-1000 on MDA-MB-
231 tumor metastasis in vivo, at the end of these studies
control and experimental animals were sacrificed, lungs,
liver, and spleen were removed and the presence of GFP-
positive tumor cells was assessed. Animals inoculated with
MDA-MB-231–GFP cells and treated with 4PEG–DX-1000
(10 mg/kg) developed significantly less number of micro-
scopic tumor metastases in their lungs and liver compared to
control animals receiving vehicle alone (Figure 4B ).
4PEG–DX-1000 Treatment Leads to a Significant
Reduction of Plasminogen and uPA Expression in
MDA-MB-231 Tumors
To further assess plasminogen and uPA expression, we
examined the MDA-MB-231 tumors growing orthotopically
by uPA and plasminogen immunohistochemical analysis to
determine whether 4PEG–DX-1000 treatment modulated
their expression. We found that 4PEG–DX-1000 treatment
reduced uPA and plasminogen expression by 55% and
63%, respectively, compared with the control-treated group
(Figure 5).
4PEG–DX-1000 Treatment Leads to a Significant
Inhibition of Tumor Cell Proliferation and a
Decrease of Tumor Vessel Hot Spots
Sections from 4PEG–DX-1000– treated tumors had
f52% less Ki-67–positive tumor cells than sections from
control-treated animals. Based on the ability of 4PEG–DX-
1000 to inhibit angiogenesis in vitro (Figure 2D), we sought to
evaluate whether 4PEG–DX-1000 had any effect on tumor
vessel formation in vivo. Sections from 4PEG–DX-1000–
treated animals hadf55% (P < .05) less CD31-positive hot
spots than sections from control-treated animals (Figure 5).
Table 1. Mouse Plasma Clearance.
Compound a Phase
Clearance (%)
a Phase
Half-Life
(minutes)
b Phase
Clearance (%)
b Phase
Half-Life
Minutes Hours
DX-1000 87 1.5 13 26.9 0.45
4PEG–DX-1000 38 18 62 750 12.5
Table 2. Rabbit Plasma Clearance.
Compound a Phase
Clearance (%)
a Phase
Half-Life
(minutes)
b Phase
Clearance (%)
b Phase
Half-Life
Minutes Hours
DX-1000 85 0.9 15 61 1.0
4PEG–DX-1000 48 123.0 52 3520 59.0
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4PEG–DX-1000 Inhibitory Effects Are Mediated by the
MAPK Signaling Pathways
Expression of MAPK and pMAPK were determined and
quantified on histologic sections of MDA-MB-231 tumors
from treated animals. We found af56% (P < .05) decreased
level of active p38–MAPK in the 4PEG–DX-1000 sections
whereas the total p38–MAPK levels were only f19% less
compared to control (Figure 5).
Discussion
Implication of pln in the major stages of cancer progression
[42,43] has fueled interest in the design and evaluation of pln-
activated prodrugs [44] and pln inhibitors as novel anticancer
therapeutic agents [45]. We used our phage display technol-
ogy to identify a human Kunitz domain–based inhibitor of
pln, DX-1000, which demonstrates high potency and spec-
ificity [29]. An inhibitor of pln that specifically blocks tumor
growth and metastases, but does not compromise hemosta-
sis, could be of major importance in tumor therapy. DX-1000
had no effect on platelet function as measured by the platelet
function and thrombelastograph analyzers and no significant
effects on global screening tests of coagulation. Fibrinolysis
was inhibited using several different types of test system, but
DX-1000 may have weaker effects in plasma or whole blood
than in buffer because about two- to four-fold higher con-
centrations appeared to be necessary to cause inhibition of
tPA-stimulated plasma clot lysis compared to that required
to inhibit pure pln or euglobulin fractions. In contrast, apro-
tinin displays lower specificity, causes prolongation of clot-
ting times, influences thrombelastography measurements,
and inhibits activated protein C, as well as pln. Side effects
caused by nonspecific pln inhibitors could have an impact on
cancer therapy. Importantly, DX-1000 demonstrated little
effect on coagulation or platelet function in our studies in vitro.
Despite significant promise of DX-1000 in vitro, chronic
administration in human patients would be challenging,
Figure 4. Effect of 4PEG–DX-1000 on MDA-MB-231–GFP tumor growth and metastasis. MDA-MB-231 tumors were allowed to grow, randomized to average
tumor volume of 60 to 70 mm3 in each group, and treated with 4PEG–DX-1000 (0.1, 1, and 10 mg/kg every day) or with vehicle alone through intraperitoneal route
for 4 weeks from the time of randomization of animals. (A) Tumor volume in control and experimental animals was determined at weekly intervals. Significant
difference from control was determined by ANOVA and is shown by asterisks (*P < .05). (B) At the end of these studies, lungs and liver from control and
experimental animals treated with 4PEG–DX-1000 (10 mg/kg) were removed and the number of metastatic tumor foci was determined as described in the
Materials and Methods section. A representative photomicrograph showing metastatic foci is shown. Results are the means ± SEM of 12 animals in each group
from two separate experiments. Significant difference in tumor foci was determined by Student’s t test and is represented by asterisks (*P < .05).
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mostly because of a high clearance and short plasma half-life.
To circumvent these problems, PEG moieties have been co-
valently attached to DX-1000. Our results demonstrated that,
by increasing the molecular mass of DX-1000 from f7 to
27 kDa through the coupling of four 5-kDa PEG moieties, we
significantly improved pharmacokinetics of DX-1000 without
significantly altering its properties as a pln inhibitor.
When evaluated in vitro, both DX-1000 and its PEGylated
derivative efficiently blocked proMMP-9 activation in tumor
cells. Activation of proMMP-9 by a pln/MMP-3 cascade has
been shown previously in a tumor cell model [46]. Our
studies demonstrated that DX-1000 and 4PEG–DX-1000
efficiently blocked the activation of proMMP-9 occurring
through the pln/MMP-3 cascade. Inhibiting this cascade
could be beneficial in cancer therapy as high MMP-9 activity
is detected in many tumors including esophageal tumors [47]
and pancreatic adenocarcinoma [48]. MMP-9 expression is
also associated with a poor prognosis in non–small cell lung
cancers [49].
To grow efficiently in vivo, tumor cells induce angiogen-
esis in both primary tumors and metastatic foci [50,51]. An-
giogenesis has become a key target in therapeutic strategies
aimed at inhibiting tumor growth and other diseases associ-
ated with neovascularization [52]. HUVEC and mouse endo-
thelial LEII cells express uPA and are thus able to initiate the
proteolytic cascade by converting plg into pln. We demon-
strated that DX-1000 and 4PEG–DX-1000 were able to
efficiently inhibit tube formation of human and mouse endo-
thelial cells, confirming the critical involvement of pln in the
angiogenic process as described by others [24,53–55].
In vivo, we examined MDA-MB-231 cancer cells as an
experimental model of an aggressive breast cancer. Accu-
mulating evidence suggests that the components of the plg–
pln system are critically involved in invasion and metastasis
of breast cancer [42,56–58]. MDA-MB-231 cells are highly
invasive and express high levels of uPA and uPAR [59,60].
Blocking uPA/uPAR interaction with a peptide derived from
the non–receptor-binding domain of uPA has been shown to
Figure 5. Effect of 4PEG–DX-1000 on angiogenesis, plg, and uPA expressions, cell proliferation, and MAPK signaling pathway. Immunohistochemical analysis of
tumor sections from control and experimental tumors treated with 4PEG–DX-1000 (10 mg/kg) to determine the expression of CD31, uPA, Ki-67, MAPK, and
pMAPK. Quantitative analysis was carried out in 10 high-power fields ( 400). Positive staining is seen in red. Change in the levels of expression was quantified by
densitometric scanning and expressed as relative density in arbitrary units (A.U.). Results are representative of the mean ± SEM of six animals in each where
significant difference from control was determined by ANOVA and shown by asterisks in right-hand panels (*P < .05).
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have antiangiogenic and proapoptotic activities in vivo
[37,61]. Our in vivo results demonstrated that, as mono-
therapy, 4PEG–DX-1000 caused a significant reduction of
MDA-MB-231 primary tumor growth. We also examined
metastases in distant organs and show that in the lungs
and liver of treated animals, the number of MDA-MB-231–
GFP cells is significantly reduced compared to that in the
control animals. Immunocytochemical analysis of the 4PEG–
DX-1000-treated tumor sections showed that this tumor
growth inhibition was associated with a significant reduction
of CD31-positive hot spots and a significant reduction of plg
and uPA expression. High levels of uPA and its inhibitor
plasminogen activator type 1 are associated with early re-
lapse and poor overall survival independent of tumor grade,
tumor size, and hormone receptor status [62–64]. Stillfried
et al. [65] showed that the invasive capacity of breast cancer
cells may be linked to the presence of high levels of active
uPA, which, in concert with bound plg, can generate large
amounts of pln at the cell surface through a positive feed-
back mechanism. Our results show that blocking pln is suf-
ficient to substantially reduce the levels of plg and uPA in a
tumor microenvironment. Immunocytochemical Ki-67 staining
of tumor sections also indicated a strong decrease of cel-
lular proliferation activity associated with a decrease in phos-
phorylation of p38–MAPK in tumor sections from 4PEG–
DX-1000–treated animals, demonstrating that tumor growth
is modulated through the MAPK pathway as described by
others [66].
Whereas further in-depth studies will elucidate the mode
of action of 4PEG–DX-1000, antitumor effects reported in
the current study can be attributed, in part, to the ability of
4PEG–DX-1000 to block plasmin-mediated activation of
several proteases (including MMPs and uPA) and latent
growth factors which can regulate the expression of these
proteins. It has been described by others that the p38–
MAPK signaling pathway is involved in the regulation of
uPA/uPAR expression and breast cancer cell invasion [67].
Our hypothesis is that 4PEG–DX-1000 indirectly diminishes
uPA expression through the p38–MAPK pathway. Both
direct (plasmin inhibition) and indirect (downregulation of
the uPA/uPAR system) effects of 4PEG–DX-1000 could
explain the antitumoral, antimetastatic, and antiangiogenic
effects that we observed.
4PEG–DX-1000 potently inhibits human pln and repre-
sents an attractive new antiproteolytic and antiangiogenic
drug candidate. Our demonstration that 4PEG–DX-1000
can retard tumor progression and metastasis in a breast
cancer model provides a rationale for its evaluation as an
antineoplastic agent.
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